Egetis Therapeutics AB (publ) (STO:EGTX)
Sweden
· Delayed Price · Currency is SEK 3.650
+0.005 (0.14%)
Mar 28, 2025, 5:29 PM CET
Egetis Therapeutics AB Revenue
In the year 2024, Egetis Therapeutics AB had annual revenue of 46.10M SEK, down -19.97%. Egetis Therapeutics AB had revenue of 10.80M in the quarter ending December 31, 2024, a decrease of -66.87%.
Revenue
46.10M
Revenue Growth
-19.97%
P/S Ratio
24.27
Revenue / Employee
1.15M
Employees
40
Market Cap
1.31B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 46.10M | -11.50M | -19.97% |
| Dec 31, 2023 | 57.60M | 35.00M | 154.87% |
| Dec 31, 2022 | 22.60M | -15.60M | -40.84% |
| Dec 31, 2021 | 38.20M | -2.46M | -6.05% |
| Dec 31, 2020 | 40.66M | -41.90M | -50.75% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Swedish Orphan Biovitrum AB | 26.03B |
| Getinge AB | 34.76B |
| Sectra AB | 3.30B |
| Camurus AB | 1.87B |
| Medicover AB | 23.97B |
| Vitrolife AB | 3.61B |
| Vimian Group AB | 4.29B |
| Elekta AB | 17.88B |